Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tervasmäki, Anna ^a,b   Winqvist, Robert ^a,b   Jukkola Vuorinen, Arja ^a   Pylkäs, Katri ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b Laboratory of Cancer Genetics and Tumor Biology   (Finland)

Author keywords

Copy number variation; CYP2C19; Triple negative breast cancer

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CASP3 GENE; CDH19 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; CYP2C19 GENE; DAB2IP GENE; DCLRE1C GENE; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; ITGA9 GENE; MAJOR CLINICAL STUDY; ONSET AGE; POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; COHORT ANALYSIS; ENZYMOLOGY; GENETICS; MIDDLE AGED; VERY ELDERLY;

CYTOCHROME P450 2C19;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYTOCHROME P-450 CYP2C19; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MIDDLE AGED; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84924412420     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-902     Document Type: Article

References (30)

1. Weischenfeldt J, Symmons O, Spitz F, Korbel JO: Phenotypic impact of genomic structural variation: insights from and for human disease. Nat Rev Genet 2013,14(2):125-138. 10.1038/nrg3373
2. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007,447(7145):661-678. 10.1038/nature05911
3. Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, Brentani H, Santos TM, Goncalves A, Nobrega AF, Pearson PL, Vianna-Morgante AM, Carraro DM, Brentani RR, Rosenberg C: Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res 2012,14(1):R24. 10.1186/bcr3109
4. Pylkäs K, Vuorela M, Otsukka M, Kallioniemi A, Jukkola-Vuorinen A, Winqvist R: Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network. PLoS Genet 2012,8(6):e1002734. 10.1371/journal.pgen.1002734
5. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH: Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin 2001,22(2):148-154.
6. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM: Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 2006,15(3):551-558. 10.1158/1055-9965.EPI-05-0801
7. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002,30(8):869-874. 10.1124/dmd.30.8.869
8. Kremmidiotis G, Baker E, Crawford J, Eyre HJ, Nahmias J, Callen DF: Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. Genomics 1998,49(3):467-471. 10.1006/geno.1998.5281
9. Hengartner MO: The biochemistry of apoptosis. Nature 2000,407(6805):770-776. 10.1038/35037710
10. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, Shimizu N: Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004,10(6):2082-2089. 10.1158/1078-0432.CCR-03-0236
11. Stratton MR, Rahman N: The emerging landscape of breast cancer susceptibility. Nat Genet 2008,40(1):17-22. 10.1038/ng.2007.53
12. Singh P, Chen C, Pal-Ghosh S, Stepp MA, Sheppard D, Van De Water L: Loss of integrin alpha9beta1 results in defects in proliferation, causing poor re-epithelialization during cutaneous wound healing. J Invest Dermatol 2009,129(1):217-228. 10.1038/jid.2008.201
13. Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA, Vinson AR, Be CL, Li S, Sorensen ES, Tam PP, Denhardt DT, Sheppard D, Choong PF, Nilsson SK: Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 2009,114(1):49-59. 10.1182/blood-2009-01-197988
14. Young BA, Taooka Y, Liu S, Askins KJ, Yokosaki Y, Thomas SM, Sheppard D: The cytoplasmic domain of the integrin alpha9 subunit requires the adaptor protein paxillin to inhibit cell spreading but promotes cell migration in a paxillin-independent manner. Mol Biol Cell 2001,12(10):3214-3225. 10.1091/mbc.12.10.3214
15. Protopopov A, Kashuba V, Zabarovska VI, Muravenko OV, Lerman MI, Klein G, Zabarovsky ER: An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies. Cancer Res 2003,63(2):404-412.
16. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006,295(21):2492-2502. 10.1001/jama.295.21.2492
17. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008,14(24):8010-8018. 10.1158/1078-0432.CCR-08-1208
18. Wedlund PJ: The CYP2C19 enzyme polymorphism. Pharmacology 2000,61(3):174-183. 10.1159/000028398
19. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994,46(4):594-598.
20. Roddam PL, Rollinson S, Kane E, Roman E, Moorman A, Cartwright R, Morgan GJ: Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 2000,10(7):605-615. 10.1097/00008571-200010000-00004
21. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006,79(1):103-113. 10.1016/j.clpt.2005.10.002
22. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L: Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008,65(5):767-774. 10.1111/j.1365-2125.2008.03104.x
23. Goldstein JA, Blaisdell J: Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996, 272:210-218.
24. Hsu HL, Woad KJ, Woodfield DG, Helsby NA: A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea. Hum Genomics 2008,3(1):17-23. 10.1186/1479-7364-3-1-17
25. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, de Mesquita HB B, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, et al.: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005,97(10):755-765. 10.1093/jnci/dji132
26. Lupski JR, Stankiewicz P: Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 2005,1(6):e49. 10.1371/journal.pgen.0010049
27. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Bruning T, Winter S, Ko YD, Brauch H: CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009,115(2):391-396. 10.1007/s10549-008-0076-4
28. Pierobon M, Frankenfeld CL: Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013,137(1):307-314. 10.1007/s10549-012-2339-3
29. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H: Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012,23(2):83-89. 10.1016/j.tem.2011.10.003
30. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007,121(11):2381-2386. 10.1002/ijc.23192